Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692594 | 0.83 | DGAT1 (0.45) | DGAT1KLKB1PDE10A | |
| SCHEMBL693604 | 0.82 | DGAT1 (0.42) | DGAT1KLKB1PDE10A | |
| SCHEMBL21740024 | 0.82 | — | — | |
| SCHEMBL7431910 | 0.80 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL21465294 | 0.79 | DGAT1 (0.43) | DGAT1KLKB1PDE10A | |
| SCHEMBL7447421 | 0.77 | DGAT1 (0.40) | DGAT1KLKB1PDE10A | |
| SCHEMBL25292277 | 0.76 | DGAT1 (0.41) | DGAT1KLKB1PDE10A | |
| SCHEMBL1485428 | 0.76 | DGAT1 (0.41) | DGAT1KLKB1PDE10A | |
| SCHEMBL12963688 | 0.76 | DGAT1 (0.50) | DGAT1KLKB1PDE10A | |
| SCHEMBL21739040 | 0.74 | DGAT1 (0.40) | DGAT1KLKB1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| CN-112888675-A | Novel sulfonylurea compound | 英夫拉索姆有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112672995-A | Novel sulfonamide urea compounds | 英夫拉索姆有限公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020035464-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | DGAT1 4663/4885KLKB1 3424/4885PDE10A 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.